step .29 I'll stop smoking, soon! Chantix is different fro other quit-smoking products in that it targets nicotine receptors in the brain, attaches to them, and blocks nicotine from reaching them. A randomized, double- blind, placebo-controlled clinical trial on Chantix was conducted with a 24-week treatment period. Partici- pants in the study were cigarette smokers who were ei- ther unwilling or unable to quit smoking in the next month but were willing to reduce their smoking and make an attempt to quit within the next three months. Subjects received either Chantix or a placebo for 24 weeks, with a target of reducing the number of cigarettes smoked by 50% or more by week 4, 75% or more by week 8, and a quit attempt by 12 weeks. The primary outcome measured was continuous absti- nence from smoking during weeks 15 through 24. Of the 760 subjects taking Chantix, 244 abstained from smoking during weeks 15 through 24, whereas 52 of the 750 subjects taking the placebo abstained during this same time period. 24 Give a 99% confidence inter- val for the difference (treatment minus placebo) in the of smokers who would abstain from smok-